Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | CASP3 | P42574 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.48 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20526769 | 1.00 | MDM4 (0.56) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29401991 | 0.90 | MDM4 (0.58) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29370319 | 0.90 | MDM4 (0.58) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL2309917 | 0.90 | MDM4 (0.58) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29908070 | 0.90 | MDM4 (0.58) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL119451 | 0.90 | MDM4 (0.58) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL119442 | 0.90 | MDM4 (0.58) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL1486199 | 0.88 | CASP3 (0.64) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL378041 | 0.88 | CASP3 (0.64) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL378040 | 0.88 | CASP3 (0.64) | MDM4TP53CASP3KMT2AMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3609876-B1 | COVALENT SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2022-03-30 | — | — | EP | disclosed |
| EP-3609876-A1 | COVALENT SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | The Regents of The University of Michigan (US) | 2020-02-19 | — | — | EP | disclosed |
| WO-2018191199-A1 | COVALENT SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-10-18 | — | — | WO | disclosed |
| US-20180289677-A1 | Covalent Small Molecule DCN1 Inhibitors and Therapeutic Methods Using the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2018-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180289677-A1 | Covalent Small Molecule DCN1 Inhibitors and Therapeutic Methods Using the Same | CAPNS1, DCLRE1A, DCUN1D2 | MDM4 3809/4885TP53 2031/4885CASP3 1823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.